WO1988003804A3 - Procede pour traiter des infections virales chez des humains, et compositions a cet effet - Google Patents

Procede pour traiter des infections virales chez des humains, et compositions a cet effet Download PDF

Info

Publication number
WO1988003804A3
WO1988003804A3 PCT/EP1987/000719 EP8700719W WO8803804A3 WO 1988003804 A3 WO1988003804 A3 WO 1988003804A3 EP 8700719 W EP8700719 W EP 8700719W WO 8803804 A3 WO8803804 A3 WO 8803804A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating viral
humans
viral infections
compositions therefor
hypoxanthine
Prior art date
Application number
PCT/EP1987/000719
Other languages
English (en)
Other versions
WO1988003804A2 (fr
Inventor
Fritz Eckstein
Gerhard Hunsmann
Heinz Hartmann
Original Assignee
Max Planck Gesellschaft
Deutsches Primatenzentrum Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19863639780 external-priority patent/DE3639780A1/de
Priority claimed from DE19873708849 external-priority patent/DE3708849A1/de
Priority claimed from US07/041,147 external-priority patent/US4880782A/en
Application filed by Max Planck Gesellschaft, Deutsches Primatenzentrum Gmbh filed Critical Max Planck Gesellschaft
Priority to DE1987907426 priority Critical patent/DE332626T1/de
Publication of WO1988003804A2 publication Critical patent/WO1988003804A2/fr
Publication of WO1988003804A3 publication Critical patent/WO1988003804A3/fr
Priority to FI892451A priority patent/FI892451A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procédé pour traiter des maladies virales chez un sujet humain consiste à appliquer des quantités efficaces du composé (I) où X est un groupe azido, un radical méthoxy ou un atome de fluor et B est thymine, uracil, guanine, cytosine, purine ou hypoxanthine si X est méthoxy ou fluor, et B est guanine, purine ou hypoxanthine si X est azido ou un sel pharmaceutiquement acceptable de ce dernier. Sont également décrits des compositions et des composés utiles dans ce procédé.
PCT/EP1987/000719 1986-11-21 1987-11-19 Procede pour traiter des infections virales chez des humains, et compositions a cet effet WO1988003804A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE1987907426 DE332626T1 (de) 1986-11-21 1987-11-19 Verfahren zur behandlung viraler infektionen bei menschen und zubereitungen dazu.
FI892451A FI892451A (fi) 1986-11-21 1989-05-19 Foerfarande med vilket virusinfektioner i maenniskor kan skoetas och kompositioner anvaenda daeri.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19863639780 DE3639780A1 (de) 1986-11-21 1986-11-21 Arzneimittel zur behandlung von viruserkrankungen
DEP3639780.6 1986-11-22
DE19873708849 DE3708849A1 (de) 1987-03-18 1987-03-18 Arzneimittel zur behandlung von viruserkrankungen
DEP3708849.1 1987-03-18
US041,147 1987-04-22
US07/041,147 US4880782A (en) 1986-11-21 1987-04-22 Method of treating viral infections in humans and compositions therefor

Publications (2)

Publication Number Publication Date
WO1988003804A2 WO1988003804A2 (fr) 1988-06-02
WO1988003804A3 true WO1988003804A3 (fr) 1988-10-06

Family

ID=27195143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1987/000719 WO1988003804A2 (fr) 1986-11-21 1987-11-19 Procede pour traiter des infections virales chez des humains, et compositions a cet effet

Country Status (6)

Country Link
EP (1) EP0332626A1 (fr)
JP (1) JPH02500364A (fr)
CA (1) CA1296330C (fr)
FI (1) FI892451A (fr)
IL (1) IL84550A (fr)
WO (1) WO1988003804A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
FR2640508B1 (fr) * 1988-12-19 1994-07-01 Dietlin Francois Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire
NZ609146A (en) 2005-09-26 2014-08-29 Gilead Pharmasset Llc Modified 4’-nucleosides as antiviral agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD209197A1 (de) * 1981-07-21 1984-04-25 Akad Wissenschaften Ddr Verfahren zur herstellung von 3'-fluor-2',3'-didesoxyguanosin
SU1053474A1 (ru) * 1982-02-08 1985-08-07 Институт биоорганической химии АН БССР 3-Фтор-2,3-дидезоксигуанозин,про вл ющий цитостатическую активность
EP0196185A2 (fr) * 1985-03-16 1986-10-01 The Wellcome Foundation Limited Nucléosides antiviraux
EP0199451A2 (fr) * 1985-03-16 1986-10-29 The Wellcome Foundation Limited Nucléosides thérapeutiques
EP0217580A2 (fr) * 1985-09-17 1987-04-08 The Wellcome Foundation Limited Nucléosides thérapeutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD279407A1 (de) * 1986-07-24 1990-06-06 Akad Wissenschaften Ddr Verfahren zur herstellung eines mittels gegen aids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD209197A1 (de) * 1981-07-21 1984-04-25 Akad Wissenschaften Ddr Verfahren zur herstellung von 3'-fluor-2',3'-didesoxyguanosin
SU1053474A1 (ru) * 1982-02-08 1985-08-07 Институт биоорганической химии АН БССР 3-Фтор-2,3-дидезоксигуанозин,про вл ющий цитостатическую активность
EP0196185A2 (fr) * 1985-03-16 1986-10-01 The Wellcome Foundation Limited Nucléosides antiviraux
EP0199451A2 (fr) * 1985-03-16 1986-10-29 The Wellcome Foundation Limited Nucléosides thérapeutiques
EP0217580A2 (fr) * 1985-09-17 1987-04-08 The Wellcome Foundation Limited Nucléosides thérapeutiques

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun., Vol. 148, No. 1, October 14, 1987, pages 78-85; Acad. Press, Inc., US, E. MATTHES et al.: "Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta", Abstract. *
Biochem. Pharm., Vol. 29, No. 12, 1980, pages 1849-1851, E. DE CLERCQ et al.: "Antiviral, antimetabolic and antineoplastic activities of 2'- of 3'-amino or -azido-substituted deoxyribonucleosides", whole document. *
Biomed. Biochim. Acta, Vol. 44, No. 10, 1985, pages K63-K73, E. MATTHES et al.: "3'-Deoxy-3'-fluorothymidinetriphosphate: Inhibitor and terminator of DNA synthesis catalysed by DNA polymerase beta, terminal deoxynucleotidyltransferase and DNA polymerase I", Abstract. *
CHEMICAL ABSTRACTS, Vol. 101, No. 19, November 5, 1984, page 740, Ref. No. 171660y; Columbus Ohio, US; & DD-A1-209197 (AKADEMIE DER WISSENSCHAFTEN DER DDR) 25-04-1984, Abstract. *
CHEMICAL ABSTRACTS, Vol. 105, No. 19, November 10, 1986, page 74, Ref. No. 165001a; Columbus, Ohio, US; & SU-A1-1053474 (INST. OF BIOORG. CHEM. AC. OF SCIENCES; BELORUSSIAN SSR), Abstract. *
Dialog Information Services, file 155: Medline 66-68; Accession No. 06296673, M. BABA et al.: "Selective inhibition of human immunodeficiency virus (HIV) by 3'-azido-2',3'-dideoxyguanosine in vitro", & Biochem. Biophys. Res. Commun, June 30, 1987, 145(3), p. 1080-6, whole document. *
J. Biol. Chem., Vol. 262, No. 5, February 1987, pages 2187-2189, Am. Soc. of Biol. Chem. Inc., US, Y. CHENG et al.: "Human immunodeficiency virus reverse transcriptase", whole document. *
J. Med. Chem., Vol. 30, No. 8, August 1987, pages 1270-1278, Am. Chem. Soc., US, P. HERDEWIJN et al.: "3'-Substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents", whole document. *
The Lancet, Vol. I, No. 8523, January 3, 1987, pages 40-41, London, GB, H. HARTMANN et al.: "Inhibition of HIV-induced cytopathogenicity in vitro by 3'-azido-2',3'-dideoxyguanosine", whole document. *

Also Published As

Publication number Publication date
WO1988003804A2 (fr) 1988-06-02
FI892451A0 (fi) 1989-05-19
IL84550A (en) 1993-07-08
CA1296330C (fr) 1992-02-25
JPH02500364A (ja) 1990-02-08
EP0332626A1 (fr) 1989-09-20
FI892451A (fi) 1989-05-19

Similar Documents

Publication Publication Date Title
CA2268703A1 (fr) Nucleosides a base de .beta.-d dioxolane sous forme d'enantiomere pur, manifestant une activite selective contre le virus de l'hepatite b
DK0805683T3 (da) 5-fluor-2',3'-umættet-pyrimidinnukleosider
AU4690989A (en) Antiviral cytosine and guanine derivatives
AU5989090A (en) Antiviral pyrimidine nucleoside
AU1489388A (en) 2',3' dideoxyribofuranoxide derivatives
DE3773892D1 (de) Medizinische verwendung von nukleosiden.
DE69024804T2 (de) Antivirale zusammensetzung
ZA931647B (en) Therapeutic nucleosides
AU4025689A (en) Method of using plant nucleoside derivatives for treatment of viral infections
EP0286825A3 (fr) Utilisation du 3'-fluro-3'-deoxythymidine pour fabriquer un médicament pour le traitement des infections virales
AU2476388A (en) Therapeutic necleosides
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
WO1988003804A3 (fr) Procede pour traiter des infections virales chez des humains, et compositions a cet effet
AU2591692A (en) Method of treating latent herpes viral infections
NO972688D0 (no) Anvendelse av aminopurin-antivirale-midler for behandling og profylakse av latente herpesvirus-infeksjoner
AU2487688A (en) Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5- ethyluracil
ES2006672A6 (es) Procedimiento para preparar formulaciones farmaceuticas a base de 3'-azido-nucleosidos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): FI JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): FI JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987907426

Country of ref document: EP

Ref document number: 892451

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1987907426

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1987907426

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987907426

Country of ref document: EP